[Management strategy for BCR-ABL negative myeloproliferative neoplasms].
Akihiko
A
Gotoh
Norio
N
Komatsu
D055808:Drug Discovery / Q000639:trends; D005091:Exons / Q000235:genetics; D016044:Fusion Proteins, bcr-abl; D006400:Hematocrit; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D058990:Molecular Targeted Therapy; D009196:Myeloproliferative Disorders / Q000235:genetics* / Q000628:therapy*; D017354:Point Mutation; D011087:Polycythemia Vera / Q000097:blood / Q000235:genetics / Q000628:therapy; D055728:Primary Myelofibrosis / Q000235:genetics / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000235:genetics / Q000628:therapy; D013927:Thrombosis / Q000517:prevention & control
D016044:Fusion Proteins, bcr-abl; C507924:JAK2 protein, human; D053614:Janus Kinase 2